GLP-1 + GCG

The molecule is a multi-residue peptide whose sequence blends GLP-1 and glucagon determinants to enable co-engagement of both class B GPCRs documented in the published literature. Backbone-stabilizing substitutions confer enzymatic resistance, and lipid-acylation chemistry on a lysine side chain drives albumin binding and extended plasma residence. Pharmacokinetic descriptors documented in published animal-model investigations include extended plasma residence under standard parenteral paradigms — characteristic of fatty-acid-acylated peptide analogs. Interaction profile in the literature spans GLP-1R cAMP activation in β-cell models, GCGR cAMP activation in hepatocyte models, and integrated metabolic-pathway research across both receptors. All activity descriptors here are framed as documented in published research rather than as effects of the supplied product. Structural confirmation of supplied lots is established by mass spectrometry and HPLC-validated purity reported on each Certificate of Analysis.

Experimental domains documented in the published literature include dual GLP-1R / GCGR binding-affinity studies, structure-activity investigations dissecting GLP-1 versus glucagon sequence determinants, hepatocyte cAMP-signaling assays via GCGR, β-cell signaling assays via GLP-1R, integrated metabolic-pathway research in animal-model contexts, energy-expenditure pathway investigations, and comparative work alongside selective GLP-1R agonists, selective GCGR agonists, and triple-agonist GLP-1/GIP/glucagon analogs. Investigators have also characterized molecules in this class in studies of signaling-bias profiling and receptor desensitization kinetics. Use in laboratory research extends to mechanism-elucidation paradigms where the construct serves as a defined dual-receptor reference. The reference standard is supplied for these and equivalent in-vitro and animal-model experimental contexts only, with no associated guidance for human, clinical, or veterinary application.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C207H317N45O65 empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. The acylation site and lipid stoichiometry are confirmed by tandem mass spectrometry when included in the lot's release specification. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Acylated peptide analogs may exhibit aggregation behavior in some buffer systems — assay-specific stability characterization is recommended. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters do not constitute preparation guidance for human or veterinary application.